|Bid||120.15 x 100|
|Ask||133.98 x 400|
|Day's range||131.12 - 133.28|
|52-week range||92.65 - 140.52|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||153.75|
Marijuana can reduce seizures in epilepsy patients, but another drug in clinical studies may work even better.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it has submitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Epidiolex® (cannabidiol or CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two highly treatment-resistant forms of childhood-onset epilepsy. GW has received Orphan Designations from the EMA for Epidiolex for the treatment of LGS, Dravet syndrome, and recently, West syndrome and Tuberous Sclerosis Complex. In October 2017, GW completed the submission of its rolling Epidiolex New Drug Application (NDA) to the United States Food and Drug Administration (FDA), also for seizures associated with LGS and Dravet syndrome.
GW Pharmaceuticals plc said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of ...
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Potential regulatory approvals, product launches, and clinical advances should make these marijuana biotech stocks winners in the new year.
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Joining the Board of Directors today are Catherine Mackey, Alicia Secor and Lord William Waldegrave. “We are very pleased to welcome these outstanding individuals to the GW Board.
Immuno-oncology was a key focus area in 2017 - will it remain so in 2018 as companies like Juno (JUNO) progress with their pipelines?
A Relative Strength Rating upgrade for GW Pharmaceuticals shows improving technical performance.
A Relative Strength Rating upgrade for GW Pharmaceuticals shows improving technical performance. Will it continue?
If you're looking for marijuana stocks that can be added to your investment portfolios, then you might want to consider these pure-play and backdoor cannabis companies.
LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing ...
GW Pharmaceuticals stock had a sluggish 2017. But just wait 'til next year.